Cell and animal models

Galantos Pharma employs transgenic cell lines and transgenic animals for selection and priorization of lead structures. The transgenic cell lines express single subtypes of human nicotinic or muscarinic aceylcholine receptors (nAChR, mAChR) in non-neuronal cell lines, the animal models express human genes indicated to be involved in familiar Alzheimer's disease. 

The transgenic cell lines are used to study the receptor subtype specificity and molecular mode of action of ligands and lead structures. In addition, they are used to determine by electrophysiological evaluatíon the APL property and potency of nicotinic ligands. Mutated nicotinic receptor transgenic cell lines are available to assess the properties of binding sites for APL at nicotinic receptors. The transgenic cell lines are available for purchase, and Galantos Pharma and several CROs are prepared to provide screening and development services with the use of them.  

Various transgenic and other animal models have been employed in our drug development studies. We have particularly focused on the 5xFAD transgenic mouse model for analyzing the effects of Memogain and other drug candidates on built-up and removal of amyloid plaques in the brain, and on other markers of AD. These studies were performed in collaboration with Dr. Montag from the IfN, Magdeburg. Assays involving cognitive paradigms, e.g. T-maze, were performed with the IfN laboratory or the CRO Neurofit, France. Memogain-induced induction of new cell growth in selected rat brain areas was tested by Dr. J Van Kampen of CNS CRC, Charlottetown, Canada.